Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Pathstone Holdings LLC

Pathstone Holdings LLC grew its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 17.0% during the third quarter, Holdings Channel.com reports. The firm owned 34,560 shares of the biopharmaceutical company’s stock after buying an additional 5,027 shares during the quarter. Pathstone Holdings LLC’s holdings in Cytokinetics were worth $1,825,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CYTK. Darwin Global Management Ltd. acquired a new position in shares of Cytokinetics during the second quarter valued at $246,074,000. Integral Health Asset Management LLC increased its holdings in shares of Cytokinetics by 122.2% during the second quarter. Integral Health Asset Management LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $54,180,000 after purchasing an additional 550,000 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Cytokinetics during the second quarter valued at $14,957,000. Great Point Partners LLC increased its holdings in shares of Cytokinetics by 134.5% during the second quarter. Great Point Partners LLC now owns 474,202 shares of the biopharmaceutical company’s stock valued at $25,692,000 after purchasing an additional 272,000 shares during the period. Finally, Ghisallo Capital Management LLC acquired a new position in Cytokinetics during the second quarter worth about $10,619,000.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CYTK shares. Royal Bank of Canada started coverage on Cytokinetics in a report on Friday, November 8th. They set an “outperform” rating and a $80.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a report on Friday, October 18th. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a report on Wednesday, September 4th. Mizuho lifted their target price on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, JPMorgan Chase & Co. lifted their target price on Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a report on Thursday, September 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.93.

Cytokinetics Trading Up 0.4 %

Shares of NASDAQ CYTK opened at $52.22 on Thursday. Cytokinetics, Incorporated has a one year low of $30.68 and a one year high of $110.25. The firm has a market capitalization of $6.16 billion, a PE ratio of -9.67 and a beta of 0.78. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The business has a 50-day moving average price of $53.39 and a two-hundred day moving average price of $54.50.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $1.21 million. During the same period in the previous year, the firm earned ($1.35) EPS. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. As a group, analysts predict that Cytokinetics, Incorporated will post -5.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Wendall Wierenga sold 4,452 shares of Cytokinetics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $52.25, for a total transaction of $232,617.00. Following the completion of the sale, the director now directly owns 24,559 shares in the company, valued at $1,283,207.75. The trade was a 15.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Fady Ibraham Malik sold 6,342 shares of Cytokinetics stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $58.48, for a total value of $370,880.16. Following the sale, the executive vice president now owns 113,878 shares of the company’s stock, valued at approximately $6,659,585.44. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,378 shares of company stock worth $3,880,287. 3.40% of the stock is currently owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.